We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 128.80 | 43 | 09:13:13 |
From May 2019 to May 2024
By Maria Armental
Inspire Pharmaceuticals Inc. has agreed to pay $5.9 million and admit to making misleading marketing claims of its drug AzaSite to settle federal fraud claims, the Justice Department said Wednesday.
Under the settlement, which was approved Monday in Manhattan U.S. District Court, company officials admitted to trying to increase sales by marketing the drug for treatments that hadn't been approved by the Food and Drug Administration. As a result of the company's misleading marketing, the authorities said, federal health care programs paid millions of dollars in false claims from 2008 through May 2011.
The drug had only been approved to treat bacterial conjunctivitis, more commonly known as pinkeye.
The case was initially filed as a whistleblower claim in 2010.
Akorn Inc. bought Inspire Pharmaceuticals from Merck & Co. in 2013.
Write to Maria Armental at maria.armental@wsj.com
Access Investor Kit for Akorn, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US0097281069
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
